Drug Trial Radar · NCT06381180
Warrior CARE: Cannabis Behavioral Health
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Sep 22, 2025
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Wayne State UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.
Conditions
- Post Traumatic Stress Disorder
- Cannabis Use
- Suicide
- Veterans
- Marijuana
Interventions
TetrahydrocannabinolDrug
Plant cannabis that will be smoked
CannabidiolDrug
Plant cannabidiol that will be smoked
PlaceboDrug
Plant will be smoked.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessing change in PTSD diagnosis and its symptom severity from pre-treatment to post-treatment using the CAPS-5 assessment.Time frame: Administered at a pre-treatment visit (at the initial screening visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).
- Assessing change in PTSD diagnosis and its symptom severity throughout the study using the PCL-5 assessmentTime frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months
- Assessing Suicidality over time using the C-SSRS assessment.Time frame: Administered at a pre-treatment visit (at the initial screening visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).
- Assessing Suicidality throughout the study using the SBQ-R assessment.Time frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months
- Assessing mood and anxiety symptoms throughout the study using the BDI-II and STAI-Y Questionnaires.Time frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wayne State University
Detroit, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.